CureGenetics Raises $17M in Series A Financing

CureGenetics Co., Ltd, a Suzhou, China-based biotechnology company dedicated to the development of life-saving medicines and molecular diagnostics using gene editing technologies, closed $17m in Series A financing.

The round was led by Qiming Venture Partners, with participation from CTS Capital and Ascendin Investment.

The company intends to use the proceeds to further optimize its gene editing and delivery platform, to sponsor IND application and clinical trials, and to develop its diverse pipelines.

Established in 2016 by Dr. Yuanyuan Xu, CEO, CureGenetics is a biotechnology company advancing gene editing and delivery platforms to develop applications of gene-editing technology in medicines and molecular diagnostics.



Join the discussion